Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03802630
Recruitment Status : Terminated (Study was terminated by sponsor due to increased incidences of AEs of special interest (intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses)
First Posted : January 14, 2019
Results First Posted : July 28, 2022
Last Update Posted : July 28, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Condition or disease Intervention/treatment Phase
Branch Retinal Vein Occlusion Drug: Brolucizumab 6 mg Drug: Aflibercept 2 mg Other: Sham injection Phase 3

Detailed Description:
The study was comprised of a Screening period (Day -28 to Day -1), Double-masked treatment period (Day 1 to Week 72) and Post-treatment follow-up period (Week 72 to Week 76). Treatment visits were scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects entered a one-year individualized flexible treatment (IFT) phase. During the IFT phase, an assessment of disease stability was performed at each monthly visit and subjects received either an active or a sham injection. Treatment with active was interrupted when disease stability was reached.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: A masked evaluating investigator was responsible for all aspects of the study except the injections and the safety assessment following the injections. An unmasked treating investigator performed the injections and assessed patient safety following the injections.
Primary Purpose: Treatment
Official Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Actual Study Start Date : July 2, 2019
Actual Primary Completion Date : July 26, 2021
Actual Study Completion Date : July 26, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: Brolucizumab 6 mg
1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
Drug: Brolucizumab 6 mg
Solution for injection (intravitreal use)
Other Names:
  • RTH258
  • ESBA1008

Other: Sham injection

Empty sterile syringe without a needle administered as a sham injection for masking purposes.

From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.


Active Comparator: Aflibercept 2 mg
1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
Drug: Aflibercept 2 mg
Solution for injection (Intravitreal use)
Other Name: EYLEA®

Other: Sham injection

Empty sterile syringe without a needle administered as a sham injection for masking purposes.

From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.





Primary Outcome Measures :
  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24 [ Time Frame: Baseline, Week 24 ]

    BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters.

    Min and max possible scores are 0-100 letters read respectively. A higher score represents better visual functioning.

    Missing and censored BCVA values were imputed by Last observation carried forward (LOCF) as the primary approach. Observed values from both scheduled and unscheduled post-baseline visits were used for the LOCF imputation. For subjects with no post-baseline BCVA value, the baseline value was carried forward.



Secondary Outcome Measures :
  1. Change From Baseline in BCVA Averaged Over Week 40 to Week 52 [ Time Frame: Baseline, Week 40 to Week 52 ]

    An average BCVA over week 40 to week 52 was calculated. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters.

    Min and max possible scores are 0-100 letters read respectively. A higher score represents better visual functioning.


  2. Change From Baseline in BCVA Averaged Over Week 64 to Week 76 [ Time Frame: Baseline, Week 64 to Week 76 ]

    An average BCVA over week 64 to week 76 was calculated. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters.

    Min and max possible scores are 0-100 letters read respectively. A higher score represents better visual functioning.


  3. Change From Baseline in BCVA by Visit up to Week 76 [ Time Frame: Baseline and every 4 weeks from baseline up to Week 76 ]

    BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters.

    Min and max possible scores are 0-100 letters read respectively. A higher score represents better visual functioning.


  4. Proportion of Participants With a Gain ≥ 5, 10 and 15 Letters in BCVA by Visit Compared to Baseline [ Time Frame: Baseline and every 4 weeks from baseline up to Week 76 ]

    The summary by visit was conducted based on the BCVA observed from each of the corresponding visits.

    BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters.

    Min and max possible scores are 0-100 letters read respectively. A higher score represents better visual functioning.

    Every 5 letters represents 1 line of vision on the reading chart.


  5. Proportion of Participants With a Loss ≥ 5, 10 and 15 Letters in BCVA by Visit Compared to Baseline [ Time Frame: Baseline and every 4 weeks from baseline up to Week 76 ]

    The summary by visit was conducted based on the BCVA observed from each of the corresponding visit.

    BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters.

    Min and max possible scores are 0-100 letters read respectively. A higher score represents better visual functioning.

    Every 5 letters represents 1 line of vision on the reading chart.


  6. Change From Baseline in CSFT Averaged Over Week 40 to Week 52 [ Time Frame: Baseline, Week 40 to Week 52 ]
    Change from baseline in central subfield thickness (CSFT) averaged over Week 40 to Week 52 , measured in µm by Spectral Domain Optical Coherence Tomography (SD-OCT)

  7. Change From Baseline in CSFT Averaged Over Week 64 to Week 76 [ Time Frame: Baseline, Week 64 to Week 76 ]
    Change from baseline in central subfield thickness (CSFT) averaged over Week 64 to Week 76, measured in µm by Spectral Domain Optical Coherence Tomography (SD-OCT)

  8. Change From Baseline in CSFT by Visit up to Week 76 [ Time Frame: Baseline, and every 4 weeks from baseline up to Week 76 ]
    Change from baseline in central subfield thickness (CSFT) measured in µm by Spectral Domain Optical Coherence Tomography (SD-OCT)

  9. Proportion of Subjects With Presence of Retinal Fluid (Intra- and/or Subretinal Fluid) in the Study Eye by Visit up to Week 76 [ Time Frame: Every 4 weeks from baseline up to Week 76 ]
    Presence of retinal fluid (intra- and/or subretinal fluid) assessed by Spectral Domain Optical Coherence Tomography (SD-OCT)

  10. Proportion of Subjects With a CSFT < 300 µm for the Study Eye by Visit up to Week 76 [ Time Frame: Every 4 weeks from Week 4 up to Week 76 ]
    Central subfield thickness (CSFT) is measured in µm by Spectral Domain Optical Coherence Tomography (SD-OCT)

  11. Number of Injections Between Week 24 and Week 52 and Between Week 24 and Week 72 [ Time Frame: Week 24 to Week 52 and Week 24 to Week 72 ]
    Number of administered injections during the individualized flexible treatment (IFT) period, between Week 24 and Week 52 and between Week 24 and Week 72 are presented

  12. Time to Recurrence After Week 20 and up to Week 76 [ Time Frame: Week 20 to Week 76 ]

    Recurrence is defined as the need for injection while showing a lack of disease stability for the first time after Week 20 and up to Week 76.

    For subjects with recurrence after the Week 20 visit, time-to-event is calculated as (first time with the lack of disease stability - the injection date on Week 20 visit + 1). For subjects without recurrence after Week 20, the censoring time will be calculated as (last visit with disease stability assessment - the injection date on Week 20 visit + 1).


  13. Number of Subjects With Ocular and Non-ocular AEs up to Week 52 and Week 76 [ Time Frame: Baseline to Week 76 ]
    Number of subjects with at least one ocular or non-ocular Adverse Events (AEs).

  14. Change From Baseline in Patient Reported Outcomes (NEI VFQ-25) at Week 24, Week 52 and Week 76 [ Time Frame: Baseline, Week 24, Week 52 and Week 76 ]

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures a patient's subjective assessment of vision-related Quality of Life (QoL).

    The 11 subscales in the VFQ-25 are general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated better vision-related quality of life.


  15. Number of Subjects According to Their Anti-drug Antibody (ADA) Titer at Screening and Week 4, Week 12, Week 24, Week 36, Week 52 and Week 76 [ Time Frame: Baseline, Week 4, Week 12, Week 24, Week 36, Week 52 and Week 76 ]
    Anti-drug antibodies (ADA) levels were assessed from subjects assigned to brolucizumab treatment only.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Patients with visual impairment due to ME secondary to BRVO diagnosed < 6 months prior to screening.
  • BCVA score between 78 and 23 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/320) at both screening and baseline visits.

Exclusion criteria

  • Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the first 12-month study period (e.g. structural damage of the fovea, vitreous hemorrhage, retinal vascular occlusion other than BRVO, retinal detachment, macular hole, or choroidal neovascularization of any cause, diabetic retinopathy (except mild non-proliferative) and diabetic macular edema). Hemiretinal vein occlusion should be excluded.
  • Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at screening or baseline
  • Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) > 25 mmHg on medication, or according to investigator's judgment, at screening or baseline
  • Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA < 20/200 at screening (except when due to conditions whose surgery may improve VA, e.g. cataract)
  • Previous treatment with any anti-VEGF therapy or investigational drugs in the study eye at any time prior to baseline
  • Previous use of intraocular or periocular steroids in study eye at any time prior to baseline
  • Macular laser photocoagulation (focal/grid) in the study eye at any time prior to baseline and peripheral laser photocoagulation in the study eye within 3 months prior to the baseline
  • Intraocular surgery in the study eye during the 3-month period prior to baseline
  • Vitreoretinal surgery in the study eye at any time prior to baseline
  • Aphakia with the absence of posterior capsule in the study eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03802630


Locations
Show Show 102 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Novartis ( Novartis Pharmaceuticals ):
Study Protocol  [PDF] June 8, 2020
Statistical Analysis Plan  [PDF] November 8, 2021

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03802630    
Other Study ID Numbers: CRTH258C2301
2018-001842-33 ( EudraCT Number )
First Posted: January 14, 2019    Key Record Dates
Results First Posted: July 28, 2022
Last Update Posted: July 28, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Visual impairment
Macular edema
Branch retinal vein occlusion
BRVO
Brolucizumab
Aflibercept
Vascular endothelial growth factor
VEGF
anti-VEGF
Additional relevant MeSH terms:
Layout table for MeSH terms
Vision Disorders
Vision, Low
Macular Edema
Retinal Vein Occlusion
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Aflibercept
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents